Frontlight ResearchEarly access
Cervical cancer trials in China
135 of 159 trials · From ClinicalTrials.gov, checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 3Not yet taking people in ChinaQL1706 Combined With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced Cervical Cancer
- Where
- Fuzhou
- Age
- 18 years to 75 years
- People
- 486
- Run by
- Fujian Cancer Hospital
See details and how to joinNCT07613567 - No phaseTaking peopleThe Efficacy of Lymph Node Dissection for Stage IIICr of Cervical Cancer(CQGOG0103)
- Where
- Chongqing
- Age
- 18 years to 70 years
- People
- 452
- Run by
- Chongqing University Cancer Hospital
See details and how to joinNCT04555226 - Phase 2Taking peopleAutologous Tumor Infiltrating Lymphocytes Injection (GT101 Injection) for the Treatment of Recurrent or Metastatic Cervical Cancer
- Where
- Beijing, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guilin, Ha’erbin, Hangzhou, Jinan, Jining, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Shanghai, Shenyang, Shenzhen, Taiyuan, Tianjin, Wuhan, Xi’an, Yibin, Zhengzhou
- Age
- 18 years to 70 years
- People
- 100
- Run by
- Grit Biotechnology
See details and how to joinNCT06241781 - Phase 3Taking peopleStudy of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
- Where
- Beijing, Changde, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Hangzhou, Harbin, Kunming, Lanzhou, Linyi, Luzhou, Nanchang, Shandong, Shanghai, Shenyang, Shenzhen, Tianjin, Wuhan, Xi'an, Yibin, Yinchuan, Zhengzhou, Zhuzhou
- Age
- 15 years and over
- People
- 800 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06079671 · EU 2023-504374-38-00 - Phase 1/2Taking peopleRinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Where
- Beijing, Changchun, Changsha, Chengdu, Chongqing, Fujian, Guangdong, Hangzhou, Henan, Hubei, Nanchang, Shanghai, Shanxi, Shengyang, Tianjin
- Age
- 18 years and over
- People
- 952 worldwide
- Run by
- Genmab
See details and how to joinNCT05579366 - Phase 1Taking peopleA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Where
- Beijing, Guangzhou, Shanghai
- Age
- 18 years and over
- People
- 460 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00 - Phase 2Taking peopleA Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Beijing, Changsha, Hangzhou, Shanghai
- Age
- 18 years and over
- People
- 111 worldwide
- Run by
- Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00 - Phase 3Taking peopleModerated Hypofractionated Online Adaptive Radiotherapy in Cervical Cancer
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 440
- Run by
- Peking Union Medical College Hospital
See details and how to joinNCT06641635 - Phase 2Taking peopleDB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- Where
- Beijing, Changsha, Chengdu, Dongguan, Henan, Hubei, Shanghai, Shenyang, Wuhan, Xi'an, Xinxiang, Xuzhou
- Age
- 18 years and over
- People
- 750 worldwide
- Run by
- DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00 - No phaseTaking peopleHydrogel Spacer During Definitive Radiotherapy for Cervical Cancer
- Where
- Tianjin
- Age
- 17 years to 75 years
- People
- 30
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07904182 - Phase 2Taking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Chengdu, Guangzhou
- Age
- 18 years and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - No phaseTaking peopleFeasibility of the "One-Finger Technique" for Identifying the Upper Left Ureter During Para-Aortic Lymphadenectomy
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 40
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT07895212 - Phase 1/2Taking peopleA Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Where
- Baoding, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Taizhou, Tianjin, Wuhan, Xi’an, Xinxiang, Zhengzhou
- Age
- 18 years and over
- People
- 862 worldwide
- Run by
- DualityBio Inc.
See details and how to joinNCT05914116 - Phase 2Taking peopleIparomlimab/Tuvonralimab Combined With Nab-paclitaxel and Cisplatin as Neoadjuvant Therapy for Locally Advanced Cervical Cancer
- Where
- Xi'an
- Age
- 18 years to 70 years
- People
- 34
- Run by
- Xijing Hospital
See details and how to joinNCT07876154 - Phase 2Taking peopleA Study of YL202 in Patients With Advanced Solid Tumors
- Where
- Changsha
- Age
- 18 years and over
- People
- 100
- Run by
- MediLink Therapeutics (Suzhou) Co., Ltd.
See details and how to joinNCT07202364 - Phase 1/2Taking peoplePhase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- Where
- Beijing, Fuzhou, Guangzhou, Shandong, Shanghai
- Age
- 18 years and over
- People
- 233 worldwide
- Run by
- Ensem Therapeutics
See details and how to joinNCT06993844 - No phaseTaking peopleStellate Ganglion Block and Dexmedetomidine for Postoperative Sleep in Women Undergoing Laparoscopic Gynecologic Surgery
- Where
- Huai'an
- Age
- 18 years to 75 years
- People
- 100
- Run by
- Catherin Zhang
See details and how to joinNCT07860203 - No phaseEnrolling by invitationCNCMT:a Multi-center, Prospective, Single-arm Study
- Where
- Wuhan
- Age
- 18 years to 75 years
- People
- 20
- Run by
- Hubei Cancer Hospital
See details and how to joinNCT06714084 - Phase 3Taking peopleA Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 424
- Run by
- Guangzhou Gloria Biosciences Co., Ltd.
See details and how to joinNCT05798819 - No phaseTaking peopleMH-ART vs CF-IMRT in Postoperative Cervical/Endometrial Cancer
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 228
- Run by
- Xiaorong Hou
See details and how to joinNCT07584161 - Phase 2Taking peopleStudy of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
- Where
- Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dongguan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jining, Kunming, Nanchang, Nanjing, Nanning, Shandong, Shanghai, Shenyang, Tianjin, Wuhan, Wuhou District, Zhengzhou
- Age
- 18 years to 64 years
- People
- 257 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06535607 · EU 2025-523947-36-00 - Phase 2Not yet taking people in ChinaPerioperative Adebrelimab for Locally Advanced Cervical Cancer
- Where
- Hefei
- Age
- 18 years to 75 years
- People
- 35
- Run by
- Anhui Provincial Hospital
See details and how to joinNCT07811375 - No phaseTaking peopleElectroacupuncture on Postoperative Urinary Retention After Radical Surgery for Cervical Cancer
- Where
- Hangzhou
- Age
- 18 years to 70 years
- People
- 208
- Run by
- Lu Chao
See details and how to joinNCT07253194 - Phase 3Not yet taking people in ChinaJSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer
- Where
- Guangzhou, Shanghai
- Age
- 18 years and over
- People
- 368
- Run by
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
See details and how to joinNCT07797153 - Phase 4Taking peopleAn Exploratory Study on the Efficacy and Safety of Enlonstobart Combined With Concurrent Radiotherapy and Chemotherapy Following Induction Therapy With Enlonstobart Plus Chemotherapy in Patients With Locally Advanced Cervical Cancer.
- Where
- Tianjin
- Age
- 18 years to 75 years
- People
- 31
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07776821